ELOXX PHARMACEUTICALS, INC. Severance Costs
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Severance Costs of $4.00 million for the 3-month period ending 2020-03-31, per its 10-K filed 2022-03-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2022-03-30
- ELOXX PHARMACEUTICALS, INC. severance costs for the quarter ending 2020-03-31 was $4.00M.
| Period end | Severance Costs 1 month | Severance Costs 3 month |
|---|---|---|
| 2020-03-31 | $4.00M 10-K · filed 2022-03-30 | |
| 2020-02-29 | $4.00M 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |